This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Unit for Hours:H

Unit for Minutes: M

Loading text: $loading

Filter redirection page URL: /en-ie/events/

Login overlay needed?:

Filter Tags:All Medical indications|All Products|All Therapy Area

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Area

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successful

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successful

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Show More Naivagation Values: 10|25|50

Previous Text label: Previous

Next Text label: Next

Show Text label: Show:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Not provided

Products

Anoro Ellipta
(umeclidinium/vilanterol inhalation powder)

Arexvy▼
(Respiratory Syncytial Virus vaccine recombinant, adjuvanted)

Dovato
(dolutegravir/lamivudine)

Ellipta inhaler

Incruse Ellipta
(umeclidinium bromide)

Jemperli▼

(Dostarlimab)

Nucala
(mepolizumab)

Omjjara ▼
(momelotinib)

Relvar Ellipta
(fluticasone furoate/vilanterol)

Shingrix
Herpes zoster vaccine (recombinant, adjuvanted)

Trelegy Ellipta
(fluticasone furoate/umeclidinium/vilanterol)

Vocabria▼ Film-Coated Tablets
(cabotegravir)

Vocabria▼ Suspension for Injection
(cabotegravir) | VOCABRIA (cabotegravir) prolonged-release suspension for injection should always be prescribed with REKAMBYS▼ (rilpivirine long acting). REKAMBYS▼, including trademark, is owned by Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare Group of Companies. Full prescribing information is available at www.ema.europa.eu

Volibris
(ambrisentan)

Zejula
(niraparib tosylate monohydrate)
oncology

Report Adverse Event

Therapy areas

Respiratory

Vaccines

HIV

Oncology

Resources

Events

Contact us

Register now

Request a contact

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.